SCHEMBL17100651

SCHEMBL17100651

Fc1ccc(Cc2noc(N3CCN(Cc4ccc(Cl)cc4)CC3)n2)cc1F

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ MAPT P10636 4/20 0.45
▸ KMT2A Q03164 3/20 0.45
▸ POLB P06746 1/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ ALDH1A1 P00352 3/20 0.44
▸ CLPP Q16740 1/20 0.44
▸ HTT P42858 1/20 0.43
▸ MEN1 O00255 2/20 0.42
▸ LMNA P02545 2/20 0.40
▸ SIGMAR1 Q99720 1/20 0.40
▸ DRD4 P21917 2/20 0.39
▸ DRD2 P14416 1/20 0.39
▸ DRD3 P35462 1/20 0.39
▸ MAPK1 P28482 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17100613 0.91 ABCC1 (0.42) SMN1; SMN2RAB9ASIGMAR1DRD4DRD2
SCHEMBL17100819 0.84 MAPT (0.47) SMN1; SMN2RAB9AMAPTKMT2APOLB
SCHEMBL17100623 0.84 KMT2A (0.57) SMN1; SMN2RAB9AMAPTKMT2APOLB
SCHEMBL17100853 0.83 NPSR1 (0.52) SMN1; SMN2RAB9AMAPTKMT2APOLB
SCHEMBL17100710 0.83 NPSR1 (0.52) SMN1; SMN2RAB9AMAPTKMT2APOLB
SCHEMBL17115076 0.81 SOS1 (0.44) CLPP
SCHEMBL17100612 0.81 HTT (0.55) SMN1; SMN2MAPTKMT2APOLBALDH1A1
SCHEMBL17100729 0.81 HTT (0.55) SMN1; SMN2MAPTKMT2APOLBALDH1A1
SCHEMBL17100670 0.80 L3MBTL1 (0.43) RAB9AL3MBTL1HTTSIGMAR1DRD2
SCHEMBL17100749 0.80 L3MBTL1 (0.43) RAB9AL3MBTL1HTTSIGMAR1DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200140400-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2020-05-07 — — US claimed
US-20170073319-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2017-03-16 — — US claimed
EP-3119774-A1 OXADIAZOLE COMPOUNDS reMynd NV (BE) 2017-01-25 — — EP claimed
WO-2015140130-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2015-09-24 — — WO claimed
US-20200140400-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2020-05-07 — — US disclosed
US-20200140400-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2020-05-07 — — US disclosed
US-10562869-B2 Oxadiazole compounds REMYND NV (BE) 2020-02-18 — — US disclosed
US-10562869-B2 Oxadiazole compounds REMYND NV (BE) 2020-02-18 — — US disclosed
US-20170073319-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2017-03-16 — — US disclosed
US-20170073319-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2017-03-16 — — US disclosed
US-20170073319-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2017-03-16 — — US disclosed
EP-3119774-A1 OXADIAZOLE COMPOUNDS reMynd NV (BE) 2017-01-25 — — EP disclosed
WO-2015140130-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2015-09-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10562869-B2 Oxadiazole compounds OXA1L, PSEN1, MAPT SMN1; SMN2 11/4885RAB9A 3737/4885MAPT 3/4885
US-20200140400-A1 OXADIAZOLE COMPOUNDS OXA1L, PSEN1, MAPT SMN1; SMN2 11/4885RAB9A 3719/4885MAPT 3/4885
US-20170073319-A1 OXADIAZOLE COMPOUNDS OXA1L, PSEN1, MAPT SMN1; SMN2 11/4885RAB9A 3737/4885MAPT 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback